• Zachary M Bauman, Keith F Killu, Megan A Rech, Jenna L Bernabei-Combs, Marika Y Gassner, Victor E Coba, Alina Tovbin, Patti L Kunkel, and Mark E Mlynarek.
• *Department of Surgical Critical Care, Henry Ford Hospital, Detroit, Michigan; †Department of Pharmacy Services, Loyola University, Chicago, Illinois; and ‡Department of Pharmacy Services, Providence Hospital, Mobile, Alabama.
• Shock. 2014 Mar 1; 41 (3): 188-92.

ObjectiveThe objective of this study was to compare vasopressor requirements between African American (AA) patients and white patients in septic shock.MethodsThis was a retrospective cohort review conducted over a 2-year period measuring total and mean dosage of various vasopressors used between two racial groups during the treatment of patients admitted with septic shock. The study included patients admitted to the intensive care unit with septic shock at an 805-bed tertiary, academic center. All septic shock patients were managed with vasopressors. Vasopressor selection, dosage, and duration were at the discretion of the treating physician. Total, mean, and duration of vasopressor dosing requirements were obtained for study participants. Comorbidities, prehospitalization antihypertensive medication requirements, intravenous fluids given during the septic shock phase, and source of infection were analyzed.ResultsOne hundred fifty-nine patients with septic shock were analyzed, of which 96 (60.4%) were AAs (P < 0.059). African Americans had higher rates of end-stage renal disease and hypertension compared with whites, 85.7% vs. 14.3% (P < 0.011; odds ratio [OR], 15.684) and 68.3% vs. 31.7% (P < 0.007; OR, 3.357), respectively. Norepinephrine (NE) was administered to 150 patients, 57.2% of which were AAs (P < 0.509). Thirteen patients received dopamine (5% AAs, P < 0.588), 40 patients received phenylephrine (15.7% AAs, P < 0.451), and five patients received epinephrine (1.9% AAs, P < 0.660). Comparing vasopressors between races, only NE showed statistical significance via logistic regression modeling for the AA race in terms of total dosage (AAs 736.8 [SD, 897.3] μg vs. whites 370 [SD, 554.2] μg, P < 0.003), duration of vasopressor used (AAs 38.38 [SD, 34.75] h vs. whites 29.09 [SD, 27.11] h, P < 0.037), and mean dosage (AAs 21.08 [SD, 22.23] μg/h vs. whites 12.37 [SD, 13.86] μg/h, P < 0.01). Mortality between groups was not significant. Logistic regression identified discrepancy of the mean dose NE in AAs compared with whites, with OR of 1.043 (P = 0.01).ConclusionsAfrican American patients with septic shock were treated with higher doses of NE and required longer duration of NE administration compared with white patients.

51 keywords...

hide…